Digital writing solution speeds up data harvest while ensuring traceability and capture ease
Digital writing solution speeds up data harvest while ensuring traceability and capture ease
Kayentis (Paris, France) is out with a digital pen and paper technology product, called Clin'Form, designed to streamline handwritten entry of clinical trial data into an electronic CRF through a collaborative, Web-based portal. The product is based on the Forms Automation System architecture using the Anoto Digital Pen & Paper technology.
Clin'Form enables a complete audit trail with full information traceability for data captured with digital pens. Also, tracking key users, including trial investigators, CRAs, and data managers, is possible, as well as study progress reports in real time on such measures as center openings, patient inclusion rates, and CRF completion follow-up. Once collected, Clin'Form facilitates the push of data to clinical data management systems in CDISC-compatible format, adding to its versatility.
Kayentis, (609) 627-5300, www.kayentis.fr
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.